whatyareckon

‘The United States Food and Drug Administration (FDA) just granted Fast Track designation for Pfizer and BioNTech’s messenger ribonucleic acid (mRNA)-based combination vaccine candidate against COVID-19 and influenza. This product, which is currently experimental, is supposed to prevent the two respiratory conditions via a single injection. Fast Track is a process designed to facilitate development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address unmet medical need. Importantly, there are only so many resources in the FDA to go around. With Pfizer and BioNTech securing access to such a program it’s to the detriment of some other biotech or pharma companies which may or may not be warranted based on the underlying details of what might be excluded. The current combined influenzas and SARS-coV-2 experimental vaccine is based on their existing Omicron bivalent vaccine that includes mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron sublineages BA.4/BA.5. But those sublineages represent now under 15% of all U.S-based infections! BQ.1 and BQ.1.1 have surged now, representing about 70% of cases. A few studies that TrialSite have tracked thus far suggest subpar performance of the current bivalent booster vaccine against these now predominant subvariants. The underlying strategy seems to benefit Pfizer’s convenience but not the safety of the public. It’s a simple game. Reuse and bundle the same technology—regardless of how good it really is—and make a lot of money.‘ for more of this article go to https://www.trialsitenews.com/a/the-game-exploit-fda-expedited-programs-the-public-in-bid-to-repurpose-bundle-increasingly-ineffective-covid-19-vaccine-with-flu-vaccine-to-monet-3e4d3501